A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 378
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2025 IOL Market Report: Global Analysis for 2024 to 2030, March, 2025
The “2025 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 12 categories of IOLs: commodity monofocal, enhanced monofocal, intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, post-op adjustable, and phakic IOLs. Additionally, 35 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
1/23/2026
BreakingCataractIOLRevenueSurgical
J&J Vision Reports 2025 Surgical Vision Revenue of $1.6 Billion
Johnson & Johnson reported Jan. 21 that its full year 2025 global surgical vision revenue was $1.6 billion, a 10.2 percent increase over $1.4 billion in 2024. Revenue was up 6.1 percent in the US a...
1/23/2026
BreakingCataractSurgical
Rayner Launches Sophi Phaco Machine in the US
UK-based Rayner reported Jan. 14 that it was launching its Sophi phacoemulsification system in the US. The unit, whose name is short for Swiss ophthalmology innovation, was developed by Swiss firm ...
1/23/2026
BreakingEuropePharmaRegulationRetina
Eylea 8 mg Gains EU Approval to Treat Macular Edema Following RVO
German drugmaker Bayer announced Jan. 16 that the European Commission had approved Eylea 8 mg, known as Eylea HD in the US, to treat patients with visual impairment due to macular edema following r...
1/21/2026
AcquisitionsDealsFundingNewsletter
Venture Capital in Ophthalmology Doubled in 2025 to Just Under $2 Billion
Venture capital investment in ophthalmology more than doubled from 2024 to 2025, totaling just under $2 billion in 2025 compared to $934.1 million in 2024. 2025 saw $1.1 billion in early-stage fund...
1/23/2026
BreakingEmergingFundingPharmaRetina
BioAge Enters Ophthalmology with Oral NLRP3 Inhibitor Candidate for DME
BioAge Labs announced Jan. 20 that it would expand development of BGE-102, an orally administered NLRP3 inhibitor, into ophthalmology with a proof-of-concept study in diabetic macular edema (DME). ...
1/23/2026
BreakingCornealDeals
BioTissue Sells Non-ophthalmic Surgical and Wound Care Business to BioStem
BioTissue Holdings reported Jan. 21 that it had sold its non-ocular surgical and wound care business to BioStem Technologies for an upfront cash payment of about $15 million, plus potential milesto...
1/23/2026
BreakingGene TherapyRegulationRetina
Nanoscope’s MCO-010 Gains Sakigake (Pioneer) and Orphan Drug Status in Japan
Nanoscope Therapeutics announced Jan. 20 that Japan’s Ministry of Health, Labour, and Welfare had granted Sakigake (Pioneer) and orphan drug designations to MCO-010 across inherited retinal disease...
1/23/2026
BreakingCataractGlaucomaIOLIndustryRetinaSurgical
BVI Medical Appoints Jim Hollingshead, PhD, as President and CEO
BVI Medical announced Jan. 19 that it had appointed Jim Hollingshead, PhD, as president and chief executive officer. Hollingshead succeeds Shervin Korangy, who will continue to serve as an advisor ...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.